NCT01551459 - A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

September 30, 2017

Study Completion Date

November 30, 2017

Conditions

Metastatic Uveal Melanoma

Interventions

DRUG

Dacarbazine

Dacarbazine: Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.

DRUG

Sunitinib

Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity

Trial Locations (1)

Clatterbridge Centre for Oncology NHS Foundation Trust, Metropolitan Borough of Wirral